IMP321 New Data Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting – Nasdaq
|
IMP321 New Data Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting
Nasdaq SYDNEY, Australia, Oct. 17, 2017 (GLOBE NEWSWIRE) — Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) ("Prima") announces that new data investigating the use of eftilagimod alpha (IMP321), the Company's lead product candidate, in combination with … |
